Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 54 | 1,706 | 28% |
| 2020 | 40 | 1,419 | 30% |
| 2021 | 56 | 1,872 | 32% |
| 2022 | 60 | 1,986 | 35% |
| 2023 | 73 | 2,432 | 38% |
| 2024 | 67 | 2,548 | 39% |
| 2025 from claims | – | 3,100 2,845–3,280 | 40% |
| 2026 forecast | – | 3,428 3,016–3,955 | 39% |
| 2027 forecast | – | 3,745 3,202–4,463 | 40% |
| 2028 forecast | – | 4,093 3,415–5,011 | 40% |
| 2029 forecast | – | 4,472 3,653–5,608 | 40% |
| 2030 forecast | – | 4,887 3,915–6,262 | 40% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 37% of the cases CMS names in Massachusetts; 42 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 50% inpatient hospital, 41% hospital outpatient, 0% surgery center, 8% office. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~3,400 | ~1,800 | ~1,400 | ~23 | ~250 |
| 2027 · ~3,700 | ~2,000 | ~1,500 | ~30 | ~270 |
| 2028 · ~4,100 | ~2,200 | ~1,600 | ~34 | ~280 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 53% (50% in 2025), hospital outpatient about 39% (41% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 191 | 8,988+5.9%/yr | +5.9%/yr | 4.3 | 12% | 14,400 in 2030+8.1%/yr |
| Pennsylvania | 139 | 4,787+8.9%/yr | +8.9%/yr | 3.0 | 14% | 7,520 in 2030+7.8%/yr |
| New Jersey | 90 | 3,940+7.1%/yr | +7.1%/yr | 3.4 | 37% | 6,480 in 2030+8.7%/yr |
| Connecticut | 35 | 1,043+11%/yr | +11%/yr | 2.7 | 5% | 1,680 in 2030+8.2%/yr |
| New Hampshire | 16 | 537+13%/yr | +13%/yr | 2.1 | 11% | 1,450 in 2030+18%/yr |
| Maine | 13 | 319+15%/yr | +15%/yr | 1.7 | 0% | 450 in 2030+5.7%/yr |
| Rhode Island | 5 | 246−0.3%/yr | −0.3%/yr | 2.3 | 0% | 350 in 2030+6.1%/yr |
| Vermont | 3 | 103−6.7%/yr | −6.7%/yr | 0.8 | 0% | 200 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 90 | 4,351−1.6%/yr | −1.6%/yr | 4.71.0× | 0% | 4,910 in 2030+2%/yr |
| EP ablation | 73 | 4,222+12%/yr | +12%/yr | 4.01.2× | 0% | 9,560 in 2030+15%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Boston Scientific leads with 90% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 4 companies reported engagement with Massachusetts’s surgeons worth $188K in consulting, speaking, meals and travel tied to these products, about $2,808 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.